UPB Upstream Bio, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 2022626 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY2.5%
TTM net income YoY-34.1%
TTM EPS YoY-128.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-6,116.0%
Net margin-5,712.3%
FCF margin—
EBITDA margin-6,108.9%
Returns
ROE-53.5%
ROA-51.5%
ROIC (approx.)-56.3%
Asset turnover0.01x
Leverage & solvency
Liabilities / assets4.9%
Debt / equity0.00x
Current ratio20.45x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.03x
Accruals ratio1.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $395,000 | $773,000 | $1.03M | $668,000 | $683,000 | $937,000 | $566,000 | $613,000 |
| R&D expense | $36.61M | $36.09M | $36.56M | $40.17M | $32.98M | $37.87M | $25.80M | $21.77M |
| SG&A expense | $7.17M | $7.05M | $8.08M | $6.67M | $5.54M | $7.42M | $6.78M | $5.16M |
| Operating income | -$43.38M | -$42.37M | -$43.62M | -$46.17M | -$37.83M | -$44.35M | -$32.01M | -$26.32M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$41.19M | -$39.70M | -$40.59M | -$42.46M | -$33.75M | -$39.97M | -$27.27M | -$21.24M |
| EBITDA | -$43.33M | -$42.32M | -$43.57M | -$46.11M | -$37.79M | -$44.30M | -$31.97M | -$26.27M |
| EPS (basic) | -0.75 | -0.73 | -0.75 | — | -0.63 | -0.74 | -0.51 | — |
| EPS (diluted) | -0.75 | -0.73 | -0.75 | — | -0.63 | -0.74 | -0.51 | — |
| Weighted avg. shares (diluted) | 54.78M | 54.57M | 54.33M | — | 53.93M | 53.77M | 53.62M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $47.42M | $79.40M | $96.72M | $101.58M | $72.16M | $45.46M | $71.31M | $325.89M |
| Short-term investments | $159.95M | $181.91M | $197.85M | $239.93M | $300.26M | $348.12M | $360.07M | $144.56M |
| Receivables | $395,000 | $772,000 | $1.03M | $668,000 | $683,000 | $937,000 | $566,000 | $613,000 |
| Current assets | $244.63M | $279.60M | $316.28M | $351.80M | $389.02M | $418.27M | $453.79M | $479.16M |
| PP&E, net | $411,000 | $460,000 | $510,000 | $559,000 | $616,000 | $544,000 | $539,000 | $582,000 |
| Goodwill | — | — | — | — | — | — | — | $0 |
| Total assets | $245.99M | $281.17M | $318.05M | $353.77M | $391.19M | $420.52M | $456.17M | $481.72M |
| Current liabilities | $11.96M | $9.99M | $13.67M | $13.45M | $11.91M | $10.93M | $9.57M | $10.74M |
| Total liabilities | $12.02M | $10.21M | $14.06M | $14.00M | $12.61M | $11.78M | $10.56M | $11.87M |
| Shareholders' equity | $233.97M | $270.96M | $304.00M | $339.77M | $378.58M | $408.74M | $445.61M | $469.85M |
| Shares outstanding | 54.81M | 54.77M | 54.42M | 54.24M | 54.00M | 53.80M | 53.64M | 53.60M |
| Cash flow statement | ||||||||
| Operating cash flow | -$54.23M | -$35.62M | -$47.85M | -$30.63M | -$22.24M | -$39.24M | -$41.16M | -$19.61M |
| Capital expenditure | $0 | — | — | $54,000 | $64,000 | — | — | $185,000 |
| Free cash flow | -$54.23M | — | — | -$30.68M | -$22.30M | — | — | -$19.80M |
| Investing cash flow | $22.18M | $15.76M | $42.40M | $58.94M | $48.19M | $12.77M | -$213.38M | $41.91M |
| Financing cash flow | $69,000 | $2.53M | $598,000 | $1.10M | $760,000 | $612,000 | -$34,000 | $270.65M |
| Depreciation & amortization | $49,000 | $50,000 | $49,000 | $57,000 | $46,000 | $42,000 | $43,000 | $49,000 |
| Stock-based compensation | $4.34M | $4.35M | $4.65M | $2.51M | $2.59M | $2.60M | $2.63M | $2.09M |
Free plan shows the latest 8 periods; Pro shows all 15 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.